Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared an article by Richard A. Furie, et al. on X:
“Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis:
Obinutuzumab = a humanized type II anti-CD20 monoclonal antibody approved in CLL.
A nice example of drug repurposing.”
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
Authors: Richard A. Furie, et al.
